Australian Clinical Labs Limited (ACL.XA)
- Previous Close
2.4600 - Open
2.4700 - Bid 2.4400 x --
- Ask --
- Day's Range
2.4600 - 2.5100 - 52 Week Range
2.2600 - 3.7000 - Volume
33,249 - Avg. Volume
89,023 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.
www.clinicallabs.com.au5,115
Full Time Employees
June 30
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: ACL.XA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACL.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACL.XA
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
2.29%
Return on Assets (ttm)
5.58%
Return on Equity (ttm)
9.19%
Revenue (ttm)
674.03M
Net Income Avi to Common (ttm)
15.43M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
25.59M
Total Debt/Equity (mrq)
198.17%
Levered Free Cash Flow (ttm)
142.17M
Company Insights: ACL.XA
ACL.XA does not have Company Insights